Search

Genmab A-S

Închisă

1,883 0.27

Rezumat

Modificarea prețului

24h

Curent

Minim

1838.5

Maxim

1897.5

Indicatori cheie

By Trading Economics

Venit

21M

52M

Vânzări

-169M

896M

P/E

Medie Sector

21.639

68.51

EPS

8.48

Marjă de profit

5.818

Angajați

3,088

EBITDA

-30M

215M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

-1.49% downside

Dividende

By Acuity

Următoarele câștiguri

6 aug. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

8.5B

113B

Deschiderea anterioară

1882.73

Închiderea anterioară

1883

Genmab A-S Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 aug. 2026, 23:56 UTC

Baidu Inc. shares are roughly flat in after-market trading, remaining near unchanged since Tuesday's close and positioned around the midpoint of its one-month range.

4 aug. 2026, 23:56 UTC

Ziff Davis Inc shares are lower during after-market hours, with no specific news identified to explain the movement. The stock fluctuated earlier in the session.

4 aug. 2026, 23:56 UTC

Centene Corp shares are higher in after-market hours, continuing a recent upward trend amid positive market sentiment following a narrowing U.S. trade deficit.

4 aug. 2026, 23:56 UTC

Insulet Corp shares are lower in after-market hours, showing little change since Tuesday's close amid a lack of specific company news.

4 aug. 2026, 23:56 UTC

Coherus BioSciences Inc shares are higher in after-market hours, reflecting strong demand since Tuesday's close amid a narrowing U.S. trade deficit.

4 aug. 2026, 23:56 UTC

Xcel Energy shares advanced in after-market trading, reaching a high of 0.60% above Tuesday's close, though still below the 20-day moving average.

4 aug. 2026, 23:56 UTC

Nasdaq Inc. shares showed routine trading activity during after-market hours, remaining roughly flat since Tuesday's close and positioned above its 20-day moving average.

4 aug. 2026, 23:56 UTC

Correlated Moves
ETF Constituents
Macro News

The iShares U.S. Aerospace & Defense ETF is trading higher in after-market hours, supported by positive earnings from technology stocks and geopolitical developments.

4 aug. 2026, 23:56 UTC

Darling Ingredients Inc shares are higher in after-market trading, rebounding from earlier session lows. No specific news was identified to explain the movement.

4 aug. 2026, 23:56 UTC

ETF Constituents

The Consumer Staples Select Sector SPDR Fund traded near unchanged in after-market hours, supported by positive contributions from Walmart, Costco, and PepsiCo.

4 aug. 2026, 23:56 UTC

Public Service Enterprise Group Inc shares are modestly higher in after-market hours. No specific company news was identified to explain the movement.

4 aug. 2026, 23:56 UTC

TE Connectivity Ltd. shares are lower in after-market trading, retracing from earlier gains. The stock remains above its 20-day moving average.

4 aug. 2026, 23:56 UTC

Correlated Moves

Skyworks Solutions Inc shares declined in after-market trading, moving lower since Tuesday's close. The stock remains above its 20-day moving average.

4 aug. 2026, 23:56 UTC

TAL Education Group shares are higher in after-market hours, recovering slightly after three consecutive sessions of decline and remaining above the 20-day moving average.

4 aug. 2026, 23:56 UTC

Packaging Corp of America shares were roughly flat in after-market hours, remaining above their 20-day moving average following three consecutive higher sessions.

4 aug. 2026, 23:56 UTC

Regions Financial Corp shares are higher in after-market hours, continuing a trend of strength following four consecutive sessions of gains.

4 aug. 2026, 23:56 UTC

Fuelcell Energy Inc shares are lower in after-market trading, with no specific company news identified to explain the decline following Tuesday's close.

4 aug. 2026, 23:56 UTC

MACOM Technology Solutions Holdings Inc. shares are lower in after-market trading, reflecting routine fluctuations and positioning below the 20-day moving average.

4 aug. 2026, 23:56 UTC

News

Starbucks Corp raised its full-year EPS guidance to approximately $2.60, reflecting strong U.S. same-store sales growth. Shares are gaining in after-market trading.

4 aug. 2026, 23:56 UTC

MKS Instruments Inc shares are lower in after-market hours, reflecting notable weakness as they remain significantly below their 20-day moving average.

4 aug. 2026, 23:56 UTC

TG Therapeutics Inc. shares are roughly flat in after-market trading. The price remains below its 20-day moving average, indicating ongoing weakness.

4 aug. 2026, 23:56 UTC

News

Alphabet Inc's market valuation is approximately $4.6 trillion, bolstered by strong second-quarter results. Shares traded higher in after-market hours, reflecting positive sentiment.

4 aug. 2026, 23:56 UTC

The US 10Y Treasury Bond Index is trading roughly flat. The U.S. trade deficit narrowed to $73.3 billion in June from $77.6 billion in May.

4 aug. 2026, 23:56 UTC

Whirlpool Corp shares are trading lower in after-market hours, with no specific news identified to explain the movement. They remain near the upper end of their one-month range.

4 aug. 2026, 23:56 UTC

CRISPR Therapeutics AG shares are lower in after-market trading, following a volatile session with no specific news identified to explain the movement.

4 aug. 2026, 23:56 UTC

News

Ameresco Inc reported second-quarter revenue of $515.5 million, a 9% increase year-over-year. Shares are trading higher in after-market hours following the results.

4 aug. 2026, 23:56 UTC

News

Advanced Energy Industries reported record Q2 revenue of $574.1 million, leading to shares trading higher in after-market hours.

4 aug. 2026, 23:56 UTC

Ultra Clean Holdings Inc. shares are higher in after-market trading, despite no specific company news identified. The broader market reflects a narrowing U.S. trade deficit.

4 aug. 2026, 23:52 UTC

Correlated Moves

Teradyne Inc. shares gained in after-market trading, reflecting positive sentiment in U.S. markets amid easing inflation concerns related to oil supply negotiations.

4 aug. 2026, 23:52 UTC

Brazil's upcoming inflation report on August 11, 2026, is poised to influence central bank policy amid rising energy prices and declining manufacturing activity.

Genmab A-S Așteptări

Obiectiv de preț

By TipRanks

-1.49% jos

Prognoză pe 12 luni

Medie 2,493.35 DKK  -1.49%

Maxim 3,320 DKK

Minim 308.417 DKK

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruGenmab A-S - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

7 ratings

3

Cumpărare

2

Păstrare

2

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
help-icon Live chat